Moleculin Biotech, Inc. (MBRX)
Largest Insider Buys in Sector
MBRX Stock Price History Chart
MBRX Stock Performance
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Insider Activity of Moleculin Biotech, Inc.
Over the last 12 months, insiders at Moleculin Biotech, Inc. have bought $159,999 and sold $0 worth of Moleculin Biotech, Inc. stock.
On average, over the past 5 years, insiders at Moleculin Biotech, Inc. have bought $175,684 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KLEMP WALTER V (CEO and President) — $129,999. Foster Jonathan P. (Chief Financial Officer) — $40,001. George Robert E. (director) — $10,000.
The last purchase of 188,404 shares for transaction amount of $129,999 was made by KLEMP WALTER V (CEO and President) on 2023‑12‑26.
List of Insider Buy and Sell Transactions, Moleculin Biotech, Inc.
| 2023-12-26 | KLEMP WALTER V | CEO and President | 188,404 0.6709% | $0.69 | $129,999 | -42.34% | ||
| 2023-12-26 | Foster Jonathan P. | Chief Financial Officer | 28,986 0.1032% | $0.69 | $20,000 | -42.34% | ||
| 2023-12-26 | George Robert E. | director | 14,493 0.0516% | $0.69 | $10,000 | -42.34% | ||
| 2022-11-25 | KLEMP WALTER V | CEO and President | 45,000 0.1562% | $1.28 | $57,632 | -49.25% | ||
| 2022-11-21 | KLEMP WALTER V | CEO and President | 22,500 0.0729% | $1.15 | $25,866 | -46.83% | ||
| 2022-11-17 | KLEMP WALTER V | CEO and President | 24,742 0.0849% | $1.02 | $25,257 | -36.28% | ||
| 2022-11-16 | KLEMP WALTER V | CEO and President | 85,213 0.2832% | $0.97 | $82,614 | -34.97% | ||
| 2017-08-16 | Sale | Priebe Waldemar | 10 percent owner | 200,000 0.6259% | $1.70 | $340,600 | -30.57% | |
| 2017-08-16 | Sale | KLEMP WALTER V | Chief Executive Officer | 200,000 0.6259% | $1.70 | $340,600 | -30.57% | |
| 2017-05-11 | KLEMP WALTER V | Chief Executive Officer | 24,000 0.133% | $0.81 | $19,440 | +128.61% | ||
| 2017-05-05 | Northcut Jacqueline | director | 2,000 0.0057% | $0.41 | $820 | +133.72% | ||
| 2017-04-28 | George Robert E. | director | 2,000 0.0058% | $0.47 | $938 | +105.49% | ||
| 2017-04-25 | Foster Jonathan P. | Exec. Vice President & CFO | 20,000 0.1113% | $0.86 | $17,298 | +114.92% |
Insider Historical Profitability
| KLEMP WALTER V | CEO and President | 680880 2.0378% | $3.45 | 6 | 1 | <0.0001% |
| Foster Jonathan P. | Chief Financial Officer | 80556 0.2411% | $3.45 | 2 | 0 | +114.92% |
| George Robert E. | director | 14660 0.0439% | $3.45 | 2 | 0 | +105.49% |
| Priebe Waldemar | 10 percent owner | 2781573 8.3249% | $3.45 | 0 | 1 | |
| Northcut Jacqueline | director | 1000 0.003% | $3.45 | 1 | 0 | +133.72% |
Institutional Investor Ownership
No records found… | |||||||